SAN

103.16

+1.52%↑

EI

266.7

-0.97%↓

SHL.DE

50.84

+0.32%↑

ARGX

549.6

-0.33%↓

FRE

39.99

-0.17%↓

SAN

103.16

+1.52%↑

EI

266.7

-0.97%↓

SHL.DE

50.84

+0.32%↑

ARGX

549.6

-0.33%↓

FRE

39.99

-0.17%↓

SAN

103.16

+1.52%↑

EI

266.7

-0.97%↓

SHL.DE

50.84

+0.32%↑

ARGX

549.6

-0.33%↓

FRE

39.99

-0.17%↓

SAN

103.16

+1.52%↑

EI

266.7

-0.97%↓

SHL.DE

50.84

+0.32%↑

ARGX

549.6

-0.33%↓

FRE

39.99

-0.17%↓

SAN

103.16

+1.52%↑

EI

266.7

-0.97%↓

SHL.DE

50.84

+0.32%↑

ARGX

549.6

-0.33%↓

FRE

39.99

-0.17%↓

Search

UCB SA

Geschlossen

BrancheGesundheitswesen

164.75 -0.87

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

164.2

Max

165.1

Schlüsselkennzahlen

By Trading Economics

Einkommen

208M

Verkäufe

2.8B

KGV

Branchendurchschnitt

32.687

73.239

Dividendenrendite

0.76

Gewinnspanne

7.453

Angestellte

9,052

EBITDA

644M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+19.23% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.76%

3.06%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.4B

34B

Vorheriger Eröffnungskurs

165.62

Vorheriger Schlusskurs

164.75

Nachrichtenstimmung

By Acuity

46%

54%

146 / 386 Ranking in Healthcare

UCB SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

28. März 2025, 16:54 UTC

Wichtige Markttreiber

Wolfspeed Shares Plunge After Report on Warning Over Chips Act Financing

29. März 2025, 11:00 UTC

Top News

Selling Your House This Spring? You Might Need to Cut the Price -- Heard on the Street -- WSJ

29. März 2025, 09:00 UTC

Ergebnisse

How the End of the 'American Exceptionalism' Trade Is Rippling Around the Globe -- WSJ

29. März 2025, 08:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

29. März 2025, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28. März 2025, 23:16 UTC

Akquisitionen, Fusionen, Übernahmen

CoreWeave Debuts: A Big IPO in a Slow Year -- Barrons.com

28. März 2025, 22:21 UTC

Top News

Inflation, Consumer Fears Fuel Stock Selloff -- WSJ

28. März 2025, 21:49 UTC

Top News

FCC Investigates Disney for DEI Practices, Chair Says -- 2nd Update

28. März 2025, 21:28 UTC

Top News

Stocks Fall on Tariff, Consumer Sentiment Fears -- WSJ

28. März 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28. März 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28. März 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28. März 2025, 20:40 UTC

Top News

OpenAI's Latest Funding Round Comes With a $20 Billion Catch -- WSJ

28. März 2025, 20:36 UTC

Top News

Consumers' Mood Sours in March With Gloomier Economic Outlook -- 4th Update

28. März 2025, 20:16 UTC

Top News

FCC Investigates Disney for DEI Practices, Chair Says -- Update

28. März 2025, 20:10 UTC

Market Talk

Consumer Staple Earnings Estimates Among Hardest Hit This Year -- Market Talk

28. März 2025, 20:07 UTC

Top News

FCC Investigates Disney for DEI Practices, Chair Says -- WSJ

28. März 2025, 19:24 UTC

Market Talk

Oil Futures Post Third Straight Weekly Gain -- Market Talk

28. März 2025, 19:24 UTC

Top News

Charlie Javice Found Guilty of Fraud in JPMorgan Case -- WSJ

28. März 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Futures Rally to Reclaim $4 Level -- Market Talk

28. März 2025, 19:00 UTC

Top News

CoreWeave Stock Bounces Around After Nvidia-Backed AI Firm Scaled Back IPO -- IBD

28. März 2025, 18:29 UTC

Market Talk

Global Equities Roundup: Market Talk

28. März 2025, 18:29 UTC

Market Talk

Gold Hits New Record With Sticky Inflation -- Market Talk

28. März 2025, 18:02 UTC

Top News

Stocks Fall on Tariff, Consumer Sentiment Fears -- WSJ

28. März 2025, 17:43 UTC

Market Talk

US Auto Sales May Crest in March as Tariffs Loom -- Market Talk

28. März 2025, 17:29 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 484 -- Market Talk

28. März 2025, 17:16 UTC

Akquisitionen, Fusionen, Übernahmen

Intel Received $1.9 Billion From Final Close of SK Hynix Deal -- Barrons.com

28. März 2025, 17:03 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, AppLovin, Lululemon, Nvidia, Wolfspeed, Argan, AAR Corp., and More -- Barrons.com

28. März 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

28. März 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer-Vergleich

Kursveränderung

UCB SA Prognose

Kursziel

By TipRanks

19.23% Vorteil

12-Monats-Prognose

Durchschnitt 94.86 EUR  19.23%

Hoch 125 EUR

Tief 74 EUR

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für UCB SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

4

Buy

1

Halten

2

Sell

Stimmung

By Acuity

146 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.